$ADTX
Aditxt, Inc. Stock $adtx

$adtx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024099697 Filed on November 18, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$6.854K
YoY Change		-94.49%
Cost Of Revenue		$467.5K
YoY Change		337.27%
Gross Profit		-$460.7K
YoY Change		-2722.88%
Gross Profit Margin		-6721.36%
Selling, General & Admin		$3.749M
YoY Change		-48.03%
% of Gross Profit
Research & Development		$491.6K
YoY Change		-45.31%
% of Gross Profit
Depreciation & Amortization		$148.3K
YoY Change		35.26%
% of Gross Profit
Operating Expenses		$4.240M
YoY Change		-47.73%
Operating Profit		-$4.701M
YoY Change		-41.93%
Interest Expense		-$2.279M
YoY Change		38.08%
% of Operating Profit
Other Income/Expense, Net		-$2.279M
YoY Change		38.08%
Pretax Income		-$6.980M
YoY Change		-28.38%
Income Tax
% Of Pretax Income
Net Earnings		-$12.85M
YoY Change		31.82%
Net Earnings / Revenue		-187445.62%
Basic Earnings Per Share		-$111.10
Diluted Earnings Per Share		-$111.10
COMMON SHARES
Basic Shares Outstanding	14.23M shares	3.603M shares
Diluted Shares Outstanding		115.7K shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$328.6K
YoY Change		-80.1%
Cash & Equivalents		$328.6K
Short-Term Investments
Other Short-Term Assets		$444.4K
YoY Change		-20.03%
Inventory		$88.99K
Prepaid Expenses		$444.4K
Receivables		$351.7K
Other Receivables		$874.7K
Total Short-Term Assets		$2.088M
YoY Change		-39.08%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.716M
YoY Change		-14.35%
Goodwill
YoY Change
Intangibles		$6.944K
YoY Change		-74.04%
Long-Term Investments		$24.54M
YoY Change		7757.69%
Other Assets
YoY Change
Total Long-Term Assets		$27.75M
YoY Change		478.42%
TOTAL ASSETS
Total Short-Term Assets		$2.088M
Total Long-Term Assets		$27.75M
Total Assets		$29.84M
YoY Change		262.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$14.59M
YoY Change		245.26%
Accrued Expenses		$678.3K
YoY Change		-37.27%
Deferred Revenue
YoY Change
Short-Term Debt		$8.840M
YoY Change		119.89%
Long-Term Debt Due		$147.8K
YoY Change		0.0%
Total Short-Term Liabilities		$24.37M
YoY Change		116.74%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$1.021M
YoY Change		-15.17%
Total Long-Term Liabilities		$1.021M
YoY Change		-15.17%
TOTAL LIABILITIES
Total Short-Term Liabilities		$24.37M
Total Long-Term Liabilities		$1.021M
Total Liabilities		$25.39M
YoY Change		103.98%
SHAREHOLDERS EQUITY
Retained Earnings		-$162.9M
YoY Change		39.66%
Common Stock		$532.00
YoY Change		44.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$201.6K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity		$4.712M
YoY Change
Total Liabilities & Shareholders Equity		$29.84M
YoY Change		262.76%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$12.85M
YoY Change		31.82%
Depreciation, Depletion And Amortization		$148.3K
YoY Change		35.26%
Cash From Operating Activities		-$2.364M
YoY Change		-70.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$1.260M
YoY Change
Cash From Investing Activities		-$1.260M
YoY Change		28471.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.862M
YoY Change		-59.75%
NET CHANGE
Cash From Operating Activities		-2.364M
Cash From Investing Activities		-1.260M
Cash From Financing Activities		3.862M
Net Change In Cash		237.4K
YoY Change		-84.71%
FREE CASH FLOW
Cash From Operating Activities		-$2.364M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39336
	dei	Entity Registrant Name EntityRegistrantName	Aditxt, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3204328
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2569 Wyandotte Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
	dei	Entity Address City Or Town EntityAddressCityOrTown	Mountain View
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94043
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	870-1200
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ADTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14234210	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	328596	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97102	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	351707	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	408326	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	88994	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	745502	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	444355	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	217390	usd
CY2024Q3	adtx	Subscription Receivable Current SubscriptionReceivableCurrent	874665	usd
CY2023Q4	adtx	Subscription Receivable Current SubscriptionReceivableCurrent	5444628	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	2088317	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6912948	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1716307	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1898243	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6944	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9444	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	102042	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	106410	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1388460	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2200299	usd
CY2024Q3	us-gaap	Investments Investments	24537211	usd
CY2023Q4	us-gaap	Investments Investments	22277211	usd
CY2023Q4	adtx	Acquisition Deposit AcquisitionDeposit	11173772	usd
CY2024Q3	us-gaap	Assets Assets	29839281	usd
CY2023Q4	us-gaap	Assets Assets	44578327	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	14585212	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8554959	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	8372685	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	15653477	usd
CY2024Q3	adtx	Financing On Fixed Assets Current FinancingOnFixedAssetsCurrent	147823	usd
CY2023Q4	adtx	Financing On Fixed Assets Current FinancingOnFixedAssetsCurrent	147823	usd
CY2024Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	117850	usd
CY2023Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	158612	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	678332	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	999943	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24368902	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25889814	usd
CY2023Q4	adtx	Settlement Liability Noncurrent SettlementLiabilityNoncurrent	1600000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	592278	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041744	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	429018	usd
CY2024Q3	us-gaap	Liabilities Liabilities	25390198	usd
CY2023Q4	us-gaap	Liabilities Liabilities	28531558	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	531353	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32998	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	531351	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32996	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	532	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	35	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167780688	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	143998994	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162867941	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127741072	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	4711719	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16056377	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-262636	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-9608	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4449083	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16046769	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29839281	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44578327	usd
CY2024Q3	us-gaap	Revenues Revenues	6854	usd
CY2023Q3	us-gaap	Revenues Revenues	124486	usd
	us-gaap	Revenues Revenues	130810	usd
	us-gaap	Revenues Revenues	563879	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	467536	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	106922	usd
	us-gaap	Cost Of Revenue CostOfRevenue	556469	usd
	us-gaap	Cost Of Revenue CostOfRevenue	470969	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	-460682	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17564	usd
	us-gaap	Gross Profit GrossProfit	-425659	usd
	us-gaap	Gross Profit GrossProfit	92910	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3718804	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7169863	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11502097	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15209789	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	491552	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	898724	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10190178	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2771100	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	44186	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	94731	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	223562	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	4240356	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	8112773	usd
	us-gaap	Operating Expenses OperatingExpenses	21787006	usd
	us-gaap	Operating Expenses OperatingExpenses	18204451	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4701038	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8095209	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22212665	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18111541	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	570114	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	906104	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4150727	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2389627	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	376	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	367	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1131	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9784	usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1709537	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	744956	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2901955	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	921242	usd
	adtx	Gain Loss On Note Exchange Agreement GainLossOnNoteExchangeAgreement	-208670	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2279275	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1650693	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7260221	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3301085	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6980313	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9745902	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29472886	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21412626	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-6980313	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-9745902	usd
	us-gaap	Profit Loss ProfitLoss	-29472886	usd
	us-gaap	Profit Loss ProfitLoss	-21412626	usd
CY2024Q3	adtx	Implied Dividends ImpliedDividends	-5907011	usd
CY2023Q3	adtx	Implied Dividends ImpliedDividends	-167169	usd
	adtx	Implied Dividends ImpliedDividends	-5907011	usd
	adtx	Implied Dividends ImpliedDividends	-167169	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-39801	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-253028	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-12847523	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9913071	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35126869	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21579795	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-111.07
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-111.07
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1950.94
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1950.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-522.86
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-522.86
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5477.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5477.66
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115672	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115672	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5081	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5081	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67182	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67182	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3940	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3940	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16046769	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	24573	usd
CY2024Q1	adtx	Stock Issued During Period Value Mdna Asset Purchase StockIssuedDuringPeriodValueMDNAAssetPurchase	1008669	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	5970443	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1600000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-14868694	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9781760	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4095	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3518567	usd
CY2024Q2	adtx	Stock Issued During Period Value Debt Issuance Costs StockIssuedDuringPeriodValueDebtIssuanceCosts	662718	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-7623879	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6343263	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	32	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1036223	usd
CY2024Q3	adtx	Stock Issued During Period Value StockIssuedDuringPeriodValue	1274792	usd
CY2024Q3	adtx	Liquidation Damages LiquidationDamages	667000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1246490	usd
CY2024Q3	adtx	Stock Issued During Period Value Issuance Of Warrants As Debt Issuance Costs StockIssuedDuringPeriodValueIssuanceOfWarrantsAsDebtIssuanceCosts	913713	usd
CY2024Q3	adtx	Stock Issued During Period Value Modifications Of Warrants As Debt Issuance Costs StockIssuedDuringPeriodValueModificationsOfWarrantsAsDebtIssuanceCosts	376901	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	-429018	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-6980313	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4449083	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5206307	usd
CY2023Q1	adtx	Adjustments To Additional Paid In Capital Share Based Compensation Stockoptionandwarrant Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockoptionandwarrantRequisiteServicePeriodRecognition	59964	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	111187	usd
CY2023Q1	adtx	Stock Issued During Period Value Sale Of Common Stock StockIssuedDuringPeriodValueSaleOfCommonStock	507016	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	168300	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-5984706	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68068	usd
CY2023Q2	adtx	Adjustments To Additional Paid In Capital Share Based Compensation Stockoptionandwarrant Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockoptionandwarrantRequisiteServicePeriodRecognition	59964	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	103264	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1581467	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-5682018	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3869255	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	59964	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	94028	usd
CY2023Q3	adtx	Stock Issued During Period Value Sale Of Series C Preferred Shares To Related Party StockIssuedDuringPeriodValueSaleOfSeriesCPreferredSharesToRelatedParty	1000	usd
CY2023Q3	adtx	Stock Issued During Period Value Debt Issuance Costs StockIssuedDuringPeriodValueDebtIssuanceCosts	272006	usd
CY2023Q3	adtx	Stock Issued During Period Value Issuance Of Warrants For Offering Net Of Issuance Costs StockIssuedDuringPeriodValueIssuanceOfWarrantsForOfferingNetOfIssuanceCosts	8966400	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	129	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-9745902	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4221630	usd
	us-gaap	Profit Loss ProfitLoss	-29472886	usd
	us-gaap	Profit Loss ProfitLoss	-21412626	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	28702	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	656671	usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	6712663	usd
	us-gaap	Depreciation Depreciation	448383	usd
	us-gaap	Depreciation Depreciation	329411	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80250	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2901955	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	921242	usd
	adtx	Gain Losses On Note Exchange Agreement GainLossesOnNoteExchangeAgreement	-208670	usd
	adtx	Modifications Of Warrants As Debt Issuance Costs ModificationsOfWarrantsAsDebtIssuanceCosts	376901	usd
	adtx	Proceeds From New Principal From Extension Of Notes Net Of Debt Discount ProceedsFromNewPrincipalFromExtensionOfNotesNetOfDebtDiscount	451974	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-56619	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-165253	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	226965	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	58762	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-4368	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-43101	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-656508	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-91987	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6568477	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2315923	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	667000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10615131	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15267550	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14407	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2260000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2260000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14407	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	467000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	687523	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4199153	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5962865	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-375000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-687523	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2330563	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2592046	usd
	adtx	Proceeds From Warrants Issued For Cash Net Of Issuance Cost ProceedsFromWarrantsIssuedForCashNetOfIssuanceCost	10547867	usd
	adtx	Proceeds From Common Stock And Warrants Issued For Cash Net Of Issuance Costs ProceedsFromCommonStockAndWarrantsIssuedForCashNetOfIssuanceCosts	6204247	usd
	adtx	Proceeds From Common Stock And Warrants Issued For Cash Net Of Issuance Costs ProceedsFromCommonStockAndWarrantsIssuedForCashNetOfIssuanceCosts	507016	usd
	adtx	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	3695298	usd
	adtx	Proceeds From Sale Of Series C Preferred Shares To Related Party ProceedsFromSaleOfSeriesCPreferredSharesToRelatedParty	1000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	129	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	262160	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1246490	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13106625	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14164671	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	231494	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1117286	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97102	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2768640	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	328596	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1651354	usd
	us-gaap	Interest Paid Net InterestPaidNet	622762	usd
	us-gaap	Interest Paid Net InterestPaidNet	1190332	usd
	us-gaap	Notes Issued1 NotesIssued1	500000	usd
	adtx	Debt Discount From Shares Issued As Inducement For Note Payable DebtDiscountFromSharesIssuedAsInducementForNotePayable	1576431	usd
	adtx	Debt Discount From Shares Issued As Inducement For Note Payable DebtDiscountFromSharesIssuedAsInducementForNotePayable	272006	usd
	adtx	Warrant Modification WarrantModification	5907011	usd
	adtx	Warrant Modification WarrantModification	167169	usd
	adtx	Issuance Of Shares In Asset Purchase IssuanceOfSharesInAssetPurchase	266448	usd
	adtx	Shares Issued For Settlement SharesIssuedForSettlement	1600000	usd
	adtx	Return Of Notes Payable From Evofem Merger Agreement ReturnOfNotesPayableFromEvofemMergerAgreement	11174426	usd
	adtx	Accrued Interest Rolled Into Notes Payable AccruedInterestRolledIntoNotesPayable	538223	usd
	adtx	Stock Receivables StockReceivables	600000	usd
	adtx	Subscription Receivable SubscriptionReceivable	874665	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	667000	usd
	adtx	Derivative Liability From Conversion Feature On Preferred Stock DerivativeLiabilityFromConversionFeatureOnPreferredStock	429018	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Company Background</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aditxt, Inc. <sup>® </sup>is an innovation platform dedicated to discovering, developing, and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company formed Adimune, Inc., a Delaware wholly owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company formed Pearsanta, Inc., a Delaware majority owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 13, 2023, the Company formed Adivir, Inc., a Delaware wholly owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2023, the Company formed Adivue, Inc., a Delaware wholly owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2023, the Company formed Adicure, Inc., which was renamed Adifem, Inc., a Delaware wholly owned subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reverse Stock Splits</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 17, 2023, the Company effectuated a 1 for 40 reverse stock split (the “2023 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on August 18, 2023. There was no change to the number of authorized shares of the Company’s common stock. All share amounts referenced in this report are adjusted to reflect the 2023 Reverse Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 2, 2024, the Company effectuated a 1 for 40 reverse stock split (the “2024 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on October 3, 2024. There was no change to the number of authorized shares of the Company’s common stock. All share amounts referenced in this report are adjusted to reflect the 2024 Reverse Split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Offerings</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2021, the Company completed a registered direct offering (“August 2021 Offering”). In connection therewith, the Company issued 58 shares of common stock, at a purchase price of $192,000.00 per share, resulting in gross proceeds of approximately $11.0 million. In a concurrent private placement, the Company issued warrants to purchase up to 58 shares. The warrants have an exercise price of $202,400.00 per share and are exercisable for a five-year period commencing six months from the date of issuance. The warrants exercise price was subsequently repriced to $120,000.00. In addition, the Company issued a warrant to the placement agent to purchase up to 3 shares of common stock at an exercise price of $240,000.00 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2021, the Company entered into an underwriting agreement with Revere Securities LLC, relating to the public offering (the “October 2021 Offering”) of 36 shares of the Company’s common stock (the “Shares”) by the Company. The Shares were offered, issued, and sold at a price to the public of $120,000.00 per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13, 2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25 million. The Company utilized a portion of the proceeds, net of underwriting discounts of approximately $3.91 million from the October 2021 Offering to fund certain obligations of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 6, 2021, the Company completed a public offering for net proceeds of $16.0 million (the “December 2021 Offering”). As part of the December 2021 Offering, we issued 104 units consisting of shares of the Company’s common stock and warrant to purchase shares of the Company’s common stock and 105 prefunded warrants. The warrant issued as part of the units had an exercise price of $92,000.00 and the prefunded warrants had an exercise price of $1.60. On June 15, 2022, the Company entered an agreement with a holder of certain warrants in the December 2021 Offering. (See Note 10)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2022, the Company completed a public offering for net proceeds of $17.2 million (the “September 2022 Offering”). As part of the September 2022 Offering, we issued 766 of shares of the Company’s common stock, pre-funded warrants to purchase 1,319 shares of common stock, and warrants to purchase 2,084 shares of the Company’s common stock. The warrants had an exercise price of $9,600.00 and the pre-funded warrants had an exercise price of $1.60.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2023, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell to such investor pre-funded warrants (the “April Pre-Funded Warrants”) to purchase up to 991 shares of common stock of the Company (the “Common Stock”) at a purchase price of $1,950.40 per April Pre-Funded Warrant. The April Pre-Funded Warrants (and shares of common stock underlying the April Pre-Funded Warrants) were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-257645), which was declared effective by the Securities and Exchange Commission on July 13, 2021. Concurrently with the sale of the April Pre-Funded Warrants, pursuant to the Purchase Agreement in a concurrent private placement, for each April Pre-Funded Warrant purchased by the investor, such investor received from the Company an unregistered warrant (the “Warrant”) to purchase two shares of Common Stock. The warrants have an exercise price of $1,376.00 per share, and are exercisable for a three year period. In addition, the Company issued a warrant to the placement agent to purchase up to 60 shares of common stock at an exercise price of $2,440.00 per share. The closing of the sales of these securities under the April Purchase Agreement took place on April 24, 2023. The gross proceeds from the offering were approximately $1.9 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2023, the “Company entered into a securities purchase agreement (the “August Purchase Agreement”) with an institutional investor for the issuance and sale in a private placement (the “August 2023 Private Placement”) of (i) pre-funded warrants (the “August Pre-Funded Warrants”) to purchase up to 25,000 shares of the Company’s common stock at an exercise price of $0.04 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 25,000 shares of the Company’s Common Stock at an exercise price of $400.00 per share. The August 2023 Private Placement closed on September 6, 2023. The net proceeds to the Company from the August 2023 Private Placement were approximately $9 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company used the net proceeds received from the August 2023 Private Placement for (i) the payment of approximately $3.1 million in outstanding obligations, (ii) the repayment of approximately $0.4 million of outstanding debt, and (iii) the balance for continuing operating expenses and working capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 29, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “December 2023 Private Placement”) of (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 30,928 shares of the Company’s common stock, par value $0.001 (the “Common Stock”) at an exercise price of $0.04 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 61,856 shares of the Company’s Common Stock, at a purchase price of $194.00 per share. The December 2023 Private Placement closed and the funds were received on January 4, 2024. The net proceeds to the Company from the December 2023 Private Placement were approximately $5.4 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company used the net proceeds received from the December 2023 Private Placement for continuing operating expenses and working capital. (Note 10)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2024, the Company entered into a Securities Purchase Agreement (the “May PIPE Purchase Agreement”) with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors in a private placement (the “May 2024 Private Placement”) (i) an aggregate of 4,186 shares of the Company’s Series C-1 Convertible Preferred Stock (the “Series C-1 Convertible Preferred Stock”), (ii) an aggregate of 4,186 shares of the Company’s Series D-1 Preferred Stock (the “Series D-1 Preferred Stock”), and (iii) warrants (the “May PIPE Warrants”) to purchase up to an aggregate of 40,328 shares of the Company’s common stock. The May 2024 Private Placement closed on May 6, 2024. The gross proceeds from the May 2024 Private Placement were approximately $4.2 million, prior to deducting the placement agent’s fees and other offering expenses payable by the Company. The Company used $1.0 million of the net proceeds to fund certain obligations under its merger agreement with Evofem Biosciences, Inc. and the remainder of the net proceeds from the offering for working capital and other general corporate purposes. (Note 10)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2024, the Company entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 4,700 shares (the “Registered Direct Shares”) of common stock of the Company (the “Common Stock”), pre-funded warrants (the “Registered Direct Pre-Funded Warrants”) to purchase up to 23,555 shares of Common Stock of the Company (the “Registered Direct Pre-Funded Warrant Shares”), having an exercise price of $0.04 per share, at a purchase price of $42.40 per share of Common Stock and a purchase price of $42.36 per Registered Direct Pre-Funded Warrant (the “Registered Direct Offering”). The shares of Common Stock and Registered Direct Pre-Funded Warrants (and shares of common stock underlying the Registered Direct Pre-Funded Warrants) were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-280757), which was declared effective by the Securities and Exchange Commission on August 6, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The closing of the sales of these securities under the Registered Direct Purchase Agreement took place on August 9, 2024. The gross proceeds from the offering were approximately $1.2 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company. The Company used $500,000 of the net proceeds from the offering to fund certain obligations under its Amended and Restated Merger Agreement with Evofem Biosciences, Inc and the remainder for working capital and other general corporate purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a limited operating history and is in the very early stages of generating revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations.</p>
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9000000	usd
CY2023Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	3100000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	400000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5400000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4200000	usd
CY2024Q2	adtx	Net Proceeds From Issuance Of Private Placement NetProceedsFromIssuanceOfPrivatePlacement	1000000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1200000	usd
	adtx	Net Proceeds Of Private Placement NetProceedsOfPrivatePlacement	500000	usd
	us-gaap	Profit Loss ProfitLoss	-29472886	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10615131	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	328596	usd
	adtx	Aggregate Amount Available To Sale AggregateAmountAvailableToSale	1800000	usd
CY2024Q3	adtx	Aggregate Market Value Of Voting And Nonvoting Equity AggregateMarketValueOfVotingAndNonvotingEquity	3000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the reserve on insurance billing, value of preferred shares issued, our investments in preferred shares, estimation of discounts on non-interest bearing borrowings, and the fair value of stock options and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all the Company’s accounts receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk is mitigated due to the Company’s number of customers. In addition, for receivables due from U.S. government agencies, the Company does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and payment is primarily dependent upon submitting the appropriate documentation.</p>
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22277211	usd
	adtx	Payment To Investment In Evofem PaymentToInvestmentInEvofem	2260000	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	24537211	usd
	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	(i) 90th calendar day after the Closing Date and (ii) 2nd Business Day after the date Evofem is notified (orally or in writing, whichever is earlier) by the SEC that such registration statement will not be reviewed or will not be subject to further review. Pursuant to the Merger Agreement, the Company is also obligated to purchase: (i) an additional 500 shares of Evofem Series F-1 Preferred Stock for an additional aggregate purchase price of $500,000 on or prior to August 9, 2024; (ii) an additional 2,000 shares of Evofem Series F-1 Preferred Stock for an additional purchase price of $2 million on the earlier of August 30, 2024 or 5 business days of the closing of a public offering by the Company resulting in aggregate net proceeds to the Company of no less than $20 million; and (iii) an additional 1,000 shares of Evofem Series F-1 Preferred Stock for an additional purchase price of $1 million on or prior to September 30, 2024. (See Note 12 for subsequent amendment)
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	49964	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
	adtx	Percentage Of Additional Shares PercentageOfAdditionalShares	0.50	pure
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	429018	usd
	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	61913	usd
CY2023	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	117291	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10190178	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2771100	usd
CY2024Q3	adtx	Quantity Issued And Outstanding QuantityIssuedAndOutstanding	704148	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1530638	shares
CY2024Q3	adtx	Antidilutive Securities Excluded From Computation Of Earnings Per Share Liquidation Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLiquidationAmount	47475730	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3415706	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1699399	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1716307	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3149258	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1251015	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1898243	usd
CY2024Q3	us-gaap	Depreciation Depreciation	148256	usd
CY2023Q3	us-gaap	Depreciation Depreciation	109611	usd
	us-gaap	Depreciation Depreciation	448383	usd
	us-gaap	Depreciation Depreciation	329411	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3149258	usd
	adtx	Brain Scientific Asset Purchase BrainScientificAssetPurchase	266448	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3415706	usd
CY2020Q4	us-gaap	Equipment Expense EquipmentExpense	19487	usd
CY2020Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	9733	usd
CY2021Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	37171	usd
CY2021Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.08	pure
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	331000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-324056	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6944	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	331000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-321556	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9444	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	833	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26750	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80250	usd
CY2023Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	321000	usd
CY2024Q3	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	321000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4470000	usd
CY2023Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3000000	usd
CY2023Q4	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1234461	usd
CY2023Q4	adtx	Net Proceeds From Note Payable NetProceedsFromNotePayable	1525539	usd
CY2023Q4	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	3129000	usd
CY2024Q1	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	5364000	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	20000	usd
CY2024Q2	us-gaap	Bridge Loan BridgeLoan	55256	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	50000	usd
CY2024Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	116806	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	93919	usd
CY2024Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	75135	usd
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	18784	usd
CY2024Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	986380	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	93919	usd
CY2024Q3	us-gaap	Senior Notes SeniorNotes	775000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	662720	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	0	usd
CY2024Q1	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	5000000	usd
CY2024Q3	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	8000000	usd
CY2023Q3	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	154480	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	15250	shares
CY2024Q1	us-gaap	Line Of Credit Facility Increase Decrease Other Net LineOfCreditFacilityIncreaseDecreaseOtherNet	208670	usd
CY2024Q1	adtx	Note Adjusted NoteAdjusted	250000	usd
CY2024Q2	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	250000	usd
CY2024Q3	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	500000	usd
	adtx	Interest Bearing Liabilities Averages Rate Paid InterestBearingLiabilitiesAveragesRatePaid	0.14	pure
	adtx	Percentage Of Utilize Proceeds PercentageOfUtilizeProceeds	1	pure
	adtx	Purchase Of Shares PurchaseOfShares	31250	shares
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	913713	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	109562	usd
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	40707	usd
	us-gaap	Payments For Rent PaymentsForRent	69379	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	25515	usd
CY2024Q3	adtx	Surrender Fee SurrenderFee	43864	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1127042	usd
CY2024Q2	adtx	Payment For Additional Rent PaymentForAdditionalRent	431182	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	159375	usd
CY2024Q2	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	590557	usd
	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	590557	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1085986	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	963213	usd
	us-gaap	Lease Cost LeaseCost	1085986	usd
	us-gaap	Lease Cost LeaseCost	963213	usd
CY2024Q3	adtx	Operating Lease Right Of Use Asset Non Current OperatingLeaseRightOfUseAssetNonCurrent	1388460	usd
CY2023Q4	adtx	Operating Lease Right Of Use Asset Non Current OperatingLeaseRightOfUseAssetNonCurrent	2200299	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1388460	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2200299	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	678332	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	999943	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	592278	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1041744	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1270610	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2041687	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M29D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	174153	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	710546	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	423930	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1308629	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	38019	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	678332	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	592278	usd
CY2020Q3	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	455000	usd
CY2022Q2	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	175000	usd
CY2024Q3	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	100000	usd
CY2023Q3	adtx	Milestone Payment MilestonePayment	175000	usd
CY2023Q3	adtx	Extension Fee ExtensionFee	100000	usd
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	70000	usd
CY2019Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	60000	usd
	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	0.0075	pure
	adtx	Expiration Period ExpirationPeriod	P3Y
CY2024Q3	adtx	Extension Fee ExtensionFee	100000	usd
CY2020Q1	us-gaap	Contractual Obligation ContractualObligation	25000	usd
	adtx	Payment For Issuance For Patents PaymentForIssuanceForPatents	25000	usd
	adtx	Payment Of Milestone Fees PaymentOfMilestoneFees	50000	usd
	us-gaap	Clearance Fees ClearanceFees	25000	usd
CY2022Q1	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	25000	usd
CY2020Q3	us-gaap	Financial Guarantee Insurance Contracts Accelerated Premium Revenue Amount FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount	10000000	usd
	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	In addition to the annual license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when Net Sales are above $5 million annually.
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1008669	usd
CY2024Q1	adtx	Aggregate Shares AggregateShares	6000	shares
CY2024Q3	us-gaap	Assets Net AssetsNet	266448	usd
CY2023Q3	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	2000000	usd
	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	1600000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	7408	shares
CY2023Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	61856	shares
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	194
CY2024Q2	adtx	Aggregate Shares Price AggregateSharesPrice	2000000	usd
CY2024Q2	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	1000000	usd
	adtx	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.40	pure
CY2024Q2	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	1000000	usd
CY2024Q2	us-gaap	Other Partners Capital OtherPartnersCapital	1500000	usd
CY2024Q3	us-gaap	Other Partners Capital OtherPartnersCapital	1000000	usd
	adtx	Number Of Dissenting Shares NumberOfDissentingShares	4141434	shares
CY2024Q1	adtx	Gross Proceeds GrossProceeds	4900000	usd
CY2024Q1	adtx	Transaction Value Percentage TransactionValuePercentage	0.10	pure
CY2024Q1	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	20000000	usd
CY2024Q3	adtx	Cash Consideration Per Share CashConsiderationPerShare	0.0467
	adtx	Aggregate Shares AggregateShares	8322	shares
CY2024Q2	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	150000000	usd
CY2024Q3	srt	Financing Receivable Nonaccrual To Outstanding Percent FinancingReceivableNonaccrualToOutstandingPercent	0.1999	pure
	adtx	Commitment Fee Shares CommitmentFeeShares	56250	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	168300	usd
	adtx	Exercisable Period ExercisablePeriod	P3Y
CY2024Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	98.8
CY2024Q2	adtx	Investors Purchase Price InvestorsPurchasePrice	0.02	pure
	adtx	Designees Warrants DesigneesWarrants	80653	shares
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	211382	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	8212	shares
	adtx	Purchase Of Shares PurchaseOfShares	31250	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4700	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	23555	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.04
CY2024Q3	us-gaap	Share Price SharePrice	42.4
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	42.36
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1200000	usd
	adtx	Payments Of Amount PaymentsOfAmount	500000	usd
	adtx	Excess Of Amount ExcessOfAmount	100000	usd
	adtx	Floor Price FloorPrice	35.52
	adtx	Percentage Of Volume Weighted Average Price PercentageOfVolumeWeightedAveragePrice	0.80	pure
	adtx	Common Stock Outstanding Owned Percentage CommonStockOutstandingOwnedPercentage	0.0499	pure
	adtx	Percentage Of Premium Of The Conversion Amount PercentageOfPremiumOfTheConversionAmount	0.50	pure
CY2024Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	162.4
	adtx	Excess Payment ExcessPayment	500000	usd
	adtx	Stock Conversion Percentage StockConversionPercentage	1.25	pure
	adtx	Preferred Stock Redemption Percentage PreferredStockRedemptionPercentage	1.15	pure
	adtx	Percentage Of Redemption Premium PercentageOfRedemptionPremium	0.25	pure
	adtx	Aggregate Amount AggregateAmount	500000	usd
	adtx	Percentage Of Conversion Amount PercentageOfConversionAmount	1.25	pure
	adtx	Percentage Of Preferred Stock PercentageOfPreferredStock	1.15	pure
	adtx	Excess Of Maximum Percentage ExcessOfMaximumPercentage	0.0499	pure
CY2021Q1	us-gaap	Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares	12500	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1172	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12883.85
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y8M26D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1172	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12883.85
	adtx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P0Y
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	59964	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	179892	usd
	adtx	Class Of Warrants Or Right Repriced ClassOfWarrantsOrRightRepriced	205767	shares
	adtx	Issuance Of New Warrants IssuanceOfNewWarrants	441315	shares
CY2024Q3	us-gaap	Dividend Income Operating DividendIncomeOperating	3474730	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	376901	usd
CY2024Q4	adtx	Bid Price BidPrice	1
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	adtx	Acquisition Deposit AcquisitionDeposit		usd
CY2024Q3	adtx	Settlement Liability Noncurrent SettlementLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	adtx	Gain Loss On Note Exchange Agreement GainLossOnNoteExchangeAgreement		usd
CY2023Q3	adtx	Gain Loss On Note Exchange Agreement GainLossOnNoteExchangeAgreement		usd
	adtx	Gain Loss On Note Exchange Agreement GainLossOnNoteExchangeAgreement		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q3	adtx	Stock Issued During Period Value Conversion Of Series A1 Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfSeriesA1ConvertiblePreferredStock		usd
CY2024Q3	adtx	Stock Issued During Period Value Modification Of Warrants StockIssuedDuringPeriodValueModificationOfWarrants		usd
CY2024Q3	adtx	Stock Issued During Period Value Rounding From Reverse Stock Split StockIssuedDuringPeriodValueRoundingFromReverseStockSplit		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q3	adtx	Stock Issued During Period Value Rounding From Reverse Stock Split StockIssuedDuringPeriodValueRoundingFromReverseStockSplit		usd
CY2023Q3	adtx	Stock Issued During Period Value Modification Of Warrants StockIssuedDuringPeriodValueModificationOfWarrants		usd
CY2023Q3	adtx	Stock Issued During Period Value Redemption Of Series C Preferred Shares To Related Party StockIssuedDuringPeriodValueRedemptionOfSeriesCPreferredSharesToRelatedParty		usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax		usd
	adtx	Gain Losses On Note Exchange Agreement GainLossesOnNoteExchangeAgreement		usd
	adtx	Modifications Of Warrants As Debt Issuance Costs ModificationsOfWarrantsAsDebtIssuanceCosts		usd
	adtx	Proceeds From New Principal From Extension Of Notes Net Of Debt Discount ProceedsFromNewPrincipalFromExtensionOfNotesNetOfDebtDiscount		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	adtx	Proceeds From Warrants Issued For Cash Net Of Issuance Cost ProceedsFromWarrantsIssuedForCashNetOfIssuanceCost		usd
	adtx	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable		usd
	adtx	Proceeds From Sale Of Series C Preferred Shares To Related Party ProceedsFromSaleOfSeriesCPreferredSharesToRelatedParty		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	adtx	Issuance Of Shares In Asset Purchase IssuanceOfSharesInAssetPurchase		usd
	adtx	Shares Issued For Settlement SharesIssuedForSettlement		usd
	adtx	Return Of Notes Payable From Evofem Merger Agreement ReturnOfNotesPayableFromEvofemMergerAgreement		usd
	adtx	Accrued Interest Rolled Into Notes Payable AccruedInterestRolledIntoNotesPayable		usd
	adtx	Stock Receivables StockReceivables		usd
	adtx	Subscription Receivable SubscriptionReceivable		usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
	adtx	Derivative Liability From Conversion Feature On Preferred Stock DerivativeLiabilityFromConversionFeatureOnPreferredStock		usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions		usd
	adtx	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	adtx	Weighted Average Remaining Life Exercised WeightedAverageRemainingLifeExercised
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	adtx	Weighted Average Remaining Life Expired Or Forfeited WeightedAverageRemainingLifeExpiredOrForfeited
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001726711

Files In Submission

Name	View Source	Status
0001213900-24-099697-index-headers.html	Edgar Link	pending
0001213900-24-099697-index.html	Edgar Link	pending
0001213900-24-099697.txt	Edgar Link	pending
0001213900-24-099697-xbrl.zip	Edgar Link	pending
adtx-20240930.xsd	Edgar Link	pending
ea0220737-10q_aditxt.htm	Edgar Link	pending
ea022073701ex31-1_aditxt.htm	Edgar Link	pending
ea022073701ex31-2_aditxt.htm	Edgar Link	pending
ea022073701ex32-1_aditxt.htm	Edgar Link	pending
adtx-20240930_cal.xml	Edgar Link	unprocessable
adtx-20240930_lab.xml	Edgar Link	unprocessable
adtx-20240930_def.xml	Edgar Link	unprocessable
adtx-20240930_pre.xml	Edgar Link	unprocessable
ea0220737-10q_aditxt_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADTX
Aditxt, Inc. Stock $adtx

2024 Q4 Form 10-Q Financial Statement

#000121390024099697 Filed on November 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX Aditxt, Inc. Stock $adtx

2024 Q4 Form 10-Q Financial Statement

#000121390024099697 Filed on November 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX
Aditxt, Inc. Stock $adtx